语言:
币种:

1 000 000 名客户选择了我们优质的服务和产品

  • 享受高达80%的折扣

    大幅折扣和促销计划

  • 快速配送且支持全球交付

    接单迅速

  • 无需出具处方

    不受限制地购买药物

  • 退款保证

    30天退款

Doctor
购物车是空的

经过认证的药店

一百多张认证证书

  • fda
  • fda
  • pgeu gpue
  • mipa
  • cipar
  • mastercard
  • visa
  • mcafee

Banners

Movfor

购买_Movfor_在线
  • Movfor 200mg

    包装 每片 特价
    200 胶囊 免费极速快递 $5.49 $1466 -26% 仅 $1097
    160 胶囊 免费极速快递 $5.60 $1173 -24% 仅 $896
    120 胶囊 免费极速快递 $5.79 $880 -21% 仅 $695
    80 胶囊 免费极速快递 $6.18 $587 -16% 仅 $494
    40 胶囊 免费普通快递 $7.33 仅 $293

Product Description

Common use
Easily distributed oral antivirals are urgently needed to treat coronavirus disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the results of a Phase 2a trial evaluating the safety, tolerability, and antiviral efficacy of molnupiravir in the treatment of COVID-19.

Dosage and direction

Eligible participants included outpatients with confirmed SARS-CoV-2 infection and symptom onset within 7 days. Participants were randomized 1:1 to 200 mg molnupiravir or placebo, or 3:1 to molnupiravir (400 or 800 mg) or placebo, twice-daily for 5 days.
Antiviral activity was assessed as time to undetectable levels of viral RNA by reverse transcriptase polymerase chain reaction and time to elimination of infectious virus isolation from nasopharyngeal swabs.

Results

Among 202 treated participants, virus isolation was significantly lower in participants receiving 800 mg molnupiravir (1.9%) versus placebo (16.7%) at Day 3 (p = 0.02). At Day 5, virus was not isolated from any participants receiving 400 or 800 mg molnupiravir, versus 11.1% of those receiving placebo (p = 0.03). Time to viral RNA clearance was decreased and a greater proportion overall achieved clearance in participants administered 800 mg molnupiravir versus placebo (p = 0.01). Molnupiravir was generally well tolerated, with similar numbers of adverse events across all groups.

Conclusions

Molnupiravir is the first oral, direct-acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile.

你可能还喜欢:

订阅 特别优惠和新闻
订阅

testimonials

    5 stars

Juan Hsia “我这辈子从来没有对哪个在线服务感到如此满意。发货很快,而且网站也很容易使用。”

下一篇用户评价